AP
DNTH icon

Antipodes Partners’s Dianthus Therapeutics DNTH Stock Holding History

Antipodes Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.5K Sell
364
-95
-21% -$5.5K ﹤0.01% 114
2025
Q4 		$18.9K Buy
+459
New +$17.8K ﹤0.01% 124

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Antipodes Partners's DNTH Position: Q1 2026 in Review

Antipodes Partners reduced its Dianthus Therapeutics (DNTH) stake by 21% in Q1 2026, selling an estimated $5.5K and leaving 364 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #114.

Antipodes Partners first reported a position in DNTH in Q4 2025 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Antipodes Partners held 364 shares of Dianthus Therapeutics worth $30.5K as of Q1 2026.
  • Antipodes Partners sold 95 Dianthus Therapeutics shares in Q1 2026, an estimated $5.5K.
  • Dianthus Therapeutics made up ﹤0.01% of Antipodes Partners's portfolio in Q1 2026, its #114 holding.
  • Antipodes Partners first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.